Despite improvements in cancer survival, cancer therapy–related cardiovascular toxicity has
risen to become a prominent clinical challenge. This has led to the growth of the burgeoning …

Immune checkpoint inhibitor (ICI) therapy represents a ground-breaking paradigm in cancer
treatment, harnessing the immune system to combat malignancies by targeting checkpoints …

CD69 is an early leukocyte activation marker involved in the regulation of the immune
response. Initial in vitro studies evaluated its function using monoclonal antibodies until …

The benefits of current state-of-the-art treatments to combat atherosclerotic cardiovascular
disease (ASCVD) have stagnated. Treatments are mostly based on controlling …

Abstract PD-1 (programed death-1)/PD-L1 (programed death-1 ligand) blockade represents
a major breakthrough of anti-cancer therapies, however, it may come with increased risk of …

Abstract Purpose of the Review Even as immune checkpoint inhibitors (ICIs) have
transformed the lifespan of many patients, they may also trigger acceleration of long-term …

Immune checkpoint inhibitors (ICIs), including cytotoxic T-lymphocyte antigen 4 (CTLA-4),
programmed cell death 1 (PD-1), and its ligand 1 (PD-L1), have improved the survival in …

Diabetes mellitus is a metabolic disorder characterized by hyperglycaemia caused by
defects in insulin synthesis, action, or both. One in every eleven people globally has …

Atherosclerosis is a complex inflammatory disease in which the adaptive immune response
plays an important role. While the overall impact of T and B cells in atherosclerosis is …

Introduction Atherosclerosis is a lipid-driven inflammatory disease of the arterial wall, and
the underlying cause of the majority of cardiovascular diseases. Recent advances in high …